NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients wi ...

"I am delighted to welcome Dennis to the Board of NRx. His unique background in both Neuroscience and Medical Technology will be an important asset to the company as we seek to develop more advanced treatments for patients," said Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx. "I have worked with Dennis previously on a highly successful digital therapeutic and know the quality he brings to our company." NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based ...

RADNOR, Pa., June 10, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company posted a new Shareholder Update Letter on its website NRx Shareholder Update and further invites interested parties to subscribe to their email alert service to stay up to date on company's progress here: NRx Email Alerts . (Note: not all updates will be included in a Press Release in the future). Today's upda ...

Financial Performance - NRx Pharmaceuticals reported a net loss reduction from $11.0 million in Q1 2023 to $6.5 million in Q1 2024, representing a 41% improvement year over year[17]. - Research and Development expenses decreased from $3.7 million in Q1 2023 to $1.7 million in Q1 2024, primarily due to a $1.6 million reduction in clinical trial expenses[17]. - NRx Pharmaceuticals has improved access to working capital by $8 million in total, including $2.9 million from equity sales and $5.1 million from Alvogen milestone advance[19]. Drug Development and Regulatory Approvals - The company plans to file a New Drug Application (NDA) for NRX-101 in the treatment of bipolar depression patients at risk of akathisia, based on positive Phase 2b/3 trial data[1][4]. - NRX-101 has been granted Qualified Infectious Disease Product (QIDP) designation, Fast Track, and Priority Review by the FDA for the treatment of complicated urinary tract infections (cUTI)[13]. - NRx has developed a patentable pH neutral formulation for ketamine, suitable for both intravenous and subcutaneous administration, with an NDA filing planned by July 2024[11]. - The company has initiated a 200-person DOD-funded trial of D-cycloserine (DCS) for chronic pain, with data expected shortly[1]. Market Potential and Partnerships - The company anticipates that if NRX-101 captures 10% of the cUTI market, it could generate hundreds of millions in annual revenue based on 3 million cases per year in the US[16]. - NRx Pharmaceuticals has partnered with Alvogen and Lotus Pharmaceuticals, receiving $5 million in milestone payments and potential future milestones of $329 million[5]. - The company plans to spin out HOPE Therapeutics, which focuses on care delivery and has received term sheets for $60 million in new investment[1]. Risk Factors and Forward-Looking Statements - The company emphasizes that forward-looking statements involve known and unknown risks, which may cause actual results to differ materially from anticipated outcomes[26]. - Investors are encouraged to review the company's most recent Annual Report on Form 10-K for detailed information on risk factors[26]. - The company does not assume any obligation to publicly update or revise forward-looking statements unless required by law[26].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38302 NRX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdic ...

RADNOR, Pa., May 8, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will participate in the EF Hutton Annual Global Conference, which will take place on May 15, 2024, at The Plaza Hotel in New York City. Prof. Jonathan Javitt, MD, MPH, the Company's Chairman and Chief Scientist, and Matthew Duffy, the Company's Chief Business Officer, will hold one-on-one meetings with investors througho ...

RADNOR, Pa., May 7, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its first quarter 2024 financial results after the market closes on Tuesday, May 14, 2024, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call to discuss the financial results as well as provide a corporate update at 4:30pm ...

Both drugs demonstrated > 50% response for treating depression. NRX-101 demonstrated a mean 76% reduction in symptoms of akathisia compared to lurasidone that was sustained over 42 days (Effect Size .37; P=0.025), using prespecified analytic methodology memorialized in FDA Special Protocol Agreement. Levels of akathisia with NRX-101 were essentially zero at day 42 This safety advantage was previously reported in the Company's published STABIL-B trial Akathisia is identified as a life-threatening side effec ...

NRX-101 is first oral antidepressant to show 33% advantage in sustained remission in suicidality (not statistically significant at this sample size) and 75% advantage in relief from Akathisia relative to lurasidone - never previously shown with an oral antidepressant. Suicidality signal met the study's promising zone criteria and the akathisia signal approached statistical significance (P=0.076)  Both NRX-101 and lurasidone, an accepted standard of care in Bipolar Depression, demonstrated approximately 50% ...

The most recent trading session ended with NRx Pharmaceuticals, Inc. (NRXP) standing at $3.14, reflecting a +0.64% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily loss of 0.46%. On the other hand, the Dow registered a loss of 0.98%, and the technology-centric Nasdaq decreased by 0.64%.Shares of the company have depreciated by 41.13% over the course of the past month, underperforming the Medical sector's loss of 4.9% and the S&P 500's loss of 3.04%.Investors will be eag ...